Skip to main content

Table 3 Multivariable binary and ordinal logistic regression analyses for mRS outcome for unmatched cohort

From: Effect of pre-stroke statin use on stroke severity and early functional recovery: a retrospective cohort study

 

Binary logistic regressiona

Ordinal logistic regressionb

 

OR

95 % CI

P-value

OR

95 % CI

P-value

Demographic

      

Age, years

0.98

(0.97–0.98)

<0.001

0.98

(0.98–0.99)

<0.001

Sex, male

1.20

(1.04–1.38)

0.012

1.08

(0.97–1.20)

0.157

Pre-stroke mRS

      

1

Ref

 

Ref

Ref

  

0

1.31

(1.06–1.63)

0.012

1.54

(1.31–1.81)

<0.001

BMI

1.00

(0.99–1.02)

0.65

1.00

(0.99–1.01)

0.64

Risk factors

      

Hypertension

1.03

(0.91–1.18)

0.63

1.01

(0.92–1.11)

0.87

DM

0.79

(0.70–0.88)

0 < .001

0.79

(0.73–0.86)

<0.001

Hyperlipidemia

0.86

(0.75–0.98)

0.024

0.94

(0.85–1.04)

0.20

Smoking

0.93

(0.82–1.07)

0.32

1.04

(0.94–1.14)

0.48

Atrial fibrillation

1.27

(1.01–1.61)

0.046

1.11

(0.94–1.14)

0.24

History of stroke

0.99

(0.85–1.16)

0.90

0.97

(0.86–1.09)

0.58

History of CAD

0.79

(0.61–1.02)

0.068

0.88

(0.73–1.06)

0.178

Lab

      

DBP, (unit 10 mmHg)

0.94

(0.91–0.98)

0.002

0.95

(0.92–0.97)

<0.001

Hemoglobin

1.04

(1.01–1.08)

0.023

1.03

(1.01–1.06)

0.015

Total cholesterol, (unit 10 mg/ dL)

0.95

(0.93–0.98)

<0.001

0.96

(0.94–0.98)

<0.001

LDL cholesterol, (unit 10 mg/ dL)

1.05

(1.01–1.08)

0.005

1.03

(1.00–1.05)

0.022

Stroke characteristics

      

Initial NIHSS score

0.76

(0.74–0.77)

<0.001

0.76

(0.75–0.76)

<0.001

Onset to arrival time

1.00

(0.99–1.00)

0.0719

0.99

(0.99–1.00)

<0.001

Stroke subtype

      

Large artery atherosclerosis

Ref

 

Ref

Ref

  

Small vessel occlusion

1.10

(0.87–1.39)

0.42

1.06

(0.90–1.26)

0.50

Cardioembolism

1.42

(1.21–1.67)

<0.001

1.13

(1.01–1.27)

0.035

Others

1.14

(0.97–1.33)

0.120

1.08

(0.96–1.21)

0.20

Pre-stroke medication

      

Antiplatelet

0.97

(0.87–1.13)

0.72

0.95

(085–1.06)

0.35

Anticoagulant

0.98

(0.72–1.33)

0.888

1.03

(0.83–1.27)

0.81

ARB or ACEI

1.11

(0.95–1.29)

0.19

1.02

(0.92–1.15)

0.67

Beta-blocker

1.40

(1.12–1.75)

0.003

1.26

(1.08–1.48)

0.003

Diuretics

1.02

(0.83–1.25)

0.86

0.97

(0.84–1.13)

0.73

Calcium channel blocker

0.92

(0.79–1.08)

0.31

1.02

(0.91–1.15)

0.71

Statin use during hospitalization

1.09

(0.95–1.25)

0.22

1.26

(1.14–1.39)

<0.001

SYSO

0.81

(0.71–0.91)

0.001

0.81

(0.74–0.89)

<0.001

Pre-stroke statin use

1.55

(1.25–1.92)

<0.001

1.30

(1.12–1.51)

0.001

  1. mRS Modified Rankin scale, BMI Body mass index, DM Diabetes mellitus, DBP Diastolic blood pressure, CAD Coronary artery disease, NIHSS National Institutes of Health Stroke Scale, ARB Angiotensin-receptor blocker, ACEI Angiotensin converting enzyme inhibitor, SYSO Symptomatic stenosis or occlusion
  2. aDependent variable: mRS 0 to 2 versus 3 to 6
  3. bDependent variable: six levels by collapsing mRS 5 and mRS 6 into a single level
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us